At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 19 enrolled
Drug / intervention
DUR-928 30 mg +2 moredrug
Likely dose
DUR-928 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open- Label, Dose Escalation Study to Assess the Safety, Pharmacokinetics and Pharmacodynamic Signals of DUR-928 in Patients With Alcoholic Hepatitis
In Brief
A Phase 2 clinical trial evaluating DUR-928 30 mg, DUR-928 90 mg, and 1 other intervention for Alcoholic Hepatitis. Completed, enrolled 19 participants across 7 sites.
Detailed Summary
This is a research trial testing DUR-928 (an experimental medication). The purpose of this trial is to assess the dose related safety, Pharmacokinetics, and Pharmacodynamics of DUR 928 in patients with moderate and severe alcoholic hepatitis (AH).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcoholic Hepatitis
CountriesUnited States
CollaboratorsCTI Clinical Trial and Consulting Services
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedFeb 2018
Enrollment StartApr 2018
Primary CompletionSep 2019
TodayJul 2026
First PostedFeb 14, 2018
Enrollment StartApr 18, 2018
Primary CompletionSep 9, 2019
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 8.4 years ago
Interventions
DUR-928 30 mgdrug
Lowest dose of 3 dose escalation arms.
DUR-928 90 mgdrug
Middle dose of 3 dose escalation arms.
DUR-928 150 mgdrug
Highest dose of 3 dose escalation arms.